Gadofosveset for Axillary Staging in Breast Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

March 31, 2012

Conditions
Breast Neoplasms
Interventions
DRUG

Gadofosveset contrast agent enhanced MRI Axilla

A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.

Trial Locations (1)

Unknown

Maastricht University Medical Center (MUMC) AZM, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER

NCT01437865 - Gadofosveset for Axillary Staging in Breast Cancer Patients | Biotech Hunter | Biotech Hunter